SGT Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Seagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$127.36 |
| 52 Week High | US$184.02 |
| 52 Week Low | US$101.34 |
| Beta | 0.57 |
| 1 Month Change | -0.30% |
| 3 Month Change | 0.094% |
| 1 Year Change | 8.78% |
| 3 Year Change | 20.15% |
| 5 Year Change | 208.75% |
| Change since IPO | 4,048.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -4.4% | 2.7% |
| 1Y | 8.8% | 6.0% | -7.1% |
Return vs Industry: SGT exceeded the German Biotechs industry which returned 6% over the past year.
Return vs Market: SGT exceeded the German Market which returned -7.1% over the past year.
Price Volatility
| SGT volatility | |
|---|---|
| SGT Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SGT is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SGT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,675 | David Epstein | https://www.seagen.com |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
| SGT fundamental statistics | |
|---|---|
| Market Cap | €23.73b |
| Earnings (TTM) | -€589.84m |
| Revenue (TTM) | €1.73b |
13.7x
P/S Ratio-40.2x
P/E RatioIs SGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGT income statement (TTM) | |
|---|---|
| Revenue | US$1.86b |
| Cost of Revenue | US$1.68b |
| Gross Profit | US$184.76m |
| Other Expenses | US$821.53m |
| Earnings | -US$636.76m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 15, 2023
| Earnings per share (EPS) | -3.43 |
| Gross Margin | 9.91% |
| Net Profit Margin | -34.16% |
| Debt/Equity Ratio | 0% |
How did SGT perform over the long term?
See historical performance and comparison